A clinical trial of ONCR-177 alone or combined with a PD-1 antibody to treat advanced and refractory cutaneous, subcutaneous, and metastatic lymph node solid tumors and HNSCC (NCT04348916) is currently under recruitment. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.